Table 1.
Demographic and clinical characteristics among the GC analytic cohort, standard-RT (70.2Gy) arm, and dose-escalated (79.2 Gy) arm in the NRG Oncology/RTOG 0126 ancillary project.
| Variable | Total | 70.2 Gy | 79.2 Gy | P value |
|---|---|---|---|---|
| Total | 215 (100) | 107 (50) | 108 (50) | |
| Age, y | ||||
| Median (range) | 70 (39, 86) | 64–74 | 65–74 | .659 |
| IQR (Q1, Q3) | 65–74 | 70 (39, 86) | 70 (57, 83) | |
| Race, no. (%) | ||||
| African American | 16 (7) | 5 (5) | 11 (10) | .313 |
| White | 190 (88) | 98 (92) | 92 (85) | |
| Other/unknown | 9 (4) | 4 (4) | 5 (5) | |
| Ethnicity, no. (%) | ||||
| Hispanic or Latino | 5 (2) | 2 (2) | 3 (3) | 1.000 |
| Non-Hispanic/Latino | 207 (96) | 104 (97) | 103 (95) | |
| Unknown | 3 (1) | 1 (1) | 2 (2) | |
| Zubrod performance status, no. (%) | ||||
| 0 | 198 (92) | 98 (92) | 100 (93) | .806 |
| 1 | 17 (8) | 9 (8) | 8 (7) | |
| PSA level at study entry (ng/mL) | ||||
| Median (range) | 7.2 (0.1, 19.0) | 4.8–10.2 | 5.2–10.3 | .894 |
| IQR (Q1, Q3) | 5.0–10.2 | 7.5 (0.1, 18.9) | 7.1 (0.6, 19.0) | |
| <10 | 154 (72) | 76 (71) | 78 (72) | .095 |
| 10 to <15 | 51 (24) | 29 (27) | 22 (20) | |
| 15–20 | 10 (5) | 2 (2) | 8 (7) | |
| Gleason score, no. (%) | ||||
| ≤(3+3) | 31 (14) | 13 (12) | 18 (17) | .341 |
| (3+4) | 132 (61) | 64 (60) | 68 (63) | |
| (4+3) | 52 (24) | 30 (28) | 22 (20) | |
| GS × PSA at study entry, no. (%) | ||||
| GS <7 and PSA (10–20 ng/mL) | 31 (14) | 13 (12) | 18 (17) | .454 |
| GS 7 and PSA <15 ng/mL | 184 (86) | 94 (88) | 90 (83) | |
| T stage, no. (%) | ||||
| T1 | 107 (50) | 50 (47) | 57 (53) | 0.453 |
| T2 | 108 (50) | 57 (53) | 51 (47) | |
| Number of NCCN I-R features, no. (%) | ||||
| 1 | 156 (73) | 76 (71) | 80 (74) | .341 |
| 2 | 52 (24) | 29 (27) | 23 (21) | |
| 3 | 7 (3) | 2 (2) | 5 (5) | |
| RT modality, no. (%) | ||||
| 3D-CRT | 137 (64) | 69 (64) | 68 (63) | .928 |
| IMRT | 78 (36) | 38 (36) | 40 (37) | |
| Follow-up for OS status (y) | ||||
| Median (range) | 12.8 (2.4, 17.7) | 11.6–14.0 | 11.8–14.0 | .988 |
| IQR (Q1, Q3) | 11.7–14.0 | 12.8 (3.7, 17.7) | 13.0 (2.4, 15.8) | |
Abbreviations: 3D-CRT = 3-dimensional conformal radiation therapy; GS = Gleason score; IMRT = intensity modulated radiation therapy; IQR = interquartile range; I-R = intermediate-risk; NCCN = National Comprehensive Cancer Network; OS = overall survival; PSA = prostate-specific antigen; Q1, Q3 = first quartile, third quartile; RT = radiation therapy.
All 215 patients with samples that passed assay quality control had complete baseline clinical and outcome information. P values were calculated using the Wilcoxon rank-sum test for continuous variables and the χ2 test or Fisher exact test for categorical variables.